BLUE BELL, Pa.--(BUSINESS WIRE)--VGX Pharmaceuticals Inc. (VGX) announced today that it has signed a license agreement with Baylor College of Medicine (BCM) covering a broad range of Growth Hormone Releasing Hormone (“GHRH”) and related intellectual property for application in humans. Under the terms of the agreement VGX will have exclusive worldwide rights to develop the technology for a number of indications including cachexia in cancer and HIV patients as well as age-related disorders. This new agreement broadens the existing relationship between the two organizations. VGX recently acquired ADViSYS, Inc., a former BCM Technologies start-up company, focused on veterinary applications of the GHRH technology. The products for porcine, canine, equine and bovine applications are in various stages of development with the porcine-GHRH product presently undergoing pre-market regulatory review in Australia.
